Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-15

FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for Triumeq, a fixed-dose combination of abacavir sulfate, dolutegravir sodium, and lamivudine, submitted by ViiV Health…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)